MAP2K7 and germ cell tumor: In term of actionability, despite some positive results of MEK inhibition in NF1-related germ cell tumors [70], none of the five patients with NF1 mutations treated with selumetinib (a MEK inhibitor) showed an objective response in the SAFIR02 trial [18].